Bellerophon Therapeutics (NASDAQ:BLPH) Research Coverage Started at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report issued on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of NASDAQ:BLPH opened at $0.06 on Wednesday. The stock’s 50-day moving average is $0.06 and its 200 day moving average is $0.05. The company has a market cap of $684,880.00, a PE ratio of -0.07 and a beta of 0.73. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $0.76.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.